# Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer

> **NCT04052113** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 152 (actual)

## Conditions studied

- Urologic Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04052113
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-25
- **Primary completion:** 2020-03-23
- **Final completion:** 2020-03-23
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2021-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052113, "Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04052113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*